Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche reports positive trial data for skin cancer drug

Roche reports positive trial data for skin cancer drug

19th January 2011

Roche has published positive new data from a phase III clinical trial of RG7204, its new treatment for the aggressive skin cancer metastatic melanoma.

According to results from the BRIM3 study, patients receiving Roche's developmental therapy were able to benefit from better rates of overall and progression-free survival compared to the current standard of care.

It means the treatment met its co-primary endpoints in the trial, demonstrating its potential as a first-in-class compound that functions by inhibiting the mutated BRAF protein found in many melanoma cases.

The drug is being developed alongside the cobas 4800 BRAF V600 Mutation Test, a diagnostic device that will help to evaluate which patients can benefit from using RG7204.

Dr Hal Barron, chief medical officer and head of global product development at Roche, said: "For the first time, a personalised investigational medicine, RG7204, has shown a significant survival benefit in metastatic melanoma."

Earlier this month, Roche completed the takeover of Marcadia Biotech, a company specialising in innovative therapies for diabetes and obesity.ADNFCR-8000103-ID-800350954-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.